Champions Oncology, Inc. financial data

Symbol
CSBR on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
855 N. Wolfe Street, Suite 619, Baltimore, MD
State of incorporation
DE
Fiscal year end
April 30
Former names
CHAMPIONS BIOTECHNOLOGY, INC. (to 3/30/2011), CHAMPIONS SPORTS INC (to 2/16/2007)
Latest financial report
10-Q - Q2 2024 - Sep 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 64.6 % -30%
Debt-to-equity -2.63K % -625%
Return On Equity 326 %
Return On Assets -12.9 % +41.9%
Operating Margin -6.73 % +52.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13.6M shares +0.85%
Common Stock, Shares, Outstanding 13.6M shares +0.81%
Entity Public Float 22M USD -21.4%
Common Stock, Value, Issued 14K USD 0%
Weighted Average Number of Shares Outstanding, Basic 13.6M shares +0.64%
Weighted Average Number of Shares Outstanding, Diluted 14M shares +3.97%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 51.7M USD -1.96%
Research and Development Expense 8.21M USD -28.3%
Selling and Marketing Expense 7.05M USD +0.59%
General and Administrative Expense 10.7M USD -1.19%
Operating Income (Loss) -3.48M USD +53.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -3.44M USD +54.2%
Income Tax Expense (Benefit) -39K USD -149%
Net Income (Loss) Attributable to Parent -3.42M USD +54.9%
Earnings Per Share, Basic -0.25 USD/shares +55.4%
Earnings Per Share, Diluted -0.26 USD/shares +53.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.89M USD -40.6%
Accounts Receivable, after Allowance for Credit Loss, Current 9.03M USD +0.36%
Assets, Current 13.2M USD -11.7%
Property, Plant and Equipment, Net 7.71M USD +10.4%
Operating Lease, Right-of-Use Asset 5.96M USD -15.9%
Goodwill 335K USD 0%
Other Assets, Noncurrent 185K USD +0.54%
Assets 24.9M USD -16.6%
Accounts Payable, Current 5.24M USD -9.1%
Accrued Liabilities, Current 2.1M USD +0.29%
Contract with Customer, Liability, Current 10.3M USD -7.1%
Liabilities, Current 19.2M USD -5.98%
Operating Lease, Liability, Noncurrent 5.74M USD -19.3%
Other Liabilities, Noncurrent 363K USD -29.4%
Liabilities 25.3M USD -9.78%
Retained Earnings (Accumulated Deficit) -83.3M USD -4.25%
Stockholders' Equity Attributable to Parent -332K USD -117%
Liabilities and Equity 24.9M USD -16.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 311K USD
Net Cash Provided by (Used in) Financing Activities -37K USD +93.7%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 13.7M shares +0.84%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 274K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.89M USD -40.6%
Deferred Tax Assets, Valuation Allowance 18.1M USD +8.06%
Deferred Tax Assets, Gross 18.1M USD +8.06%
Operating Lease, Liability 7.11M USD -14.9%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 13.3M USD -17.7%
Property, Plant and Equipment, Gross 16.1M USD -2.04%
Operating Lease, Liability, Current 1.37M USD +10%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.92M USD -1.15%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.95M USD +1.65%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.2M USD -20.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.87M USD -1.68%
Deferred Tax Assets, Operating Loss Carryforwards 9.04M USD -7.36%
Unrecognized Tax Benefits 181K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.39M USD -16.6%
Depreciation, Depletion and Amortization 1.7M USD -15.5%
Share-based Payment Arrangement, Expense 953K USD -11.8%